Skip to main content

Table 5 Baseline to post-randomisation follow-up correlations by outcome

From: Sample size estimation for randomised controlled trials with repeated assessment of patient-reported outcomes: what correlation between baseline and follow-up outcomes should we assume?

Outcome

Pearson baseline to post-randomisation follow-up correlation

Mean

Median

SD

Minimum

Maximum

No. of correlations

B-IPQ

0.6

0.6

0

0.6

0.61

2

BACK PAIN

0.24

0.19

0.11

0.17

0.37

3

Barthel Score

0.53

0.53

0.1

0.45

0.6

2

BPRS

0.57

0.57

0.12

0.49

0.65

2

CORE Functioning Dimension

0.56

0.57

0.02

0.54

0.58

3

CORE Risk Dimension

0.26

0.27

0.07

0.19

0.32

3

CORE Symptoms Dimension

0.5

0.49

0.03

0.47

0.54

3

CORE Total Score

0.55

0.53

0.03

0.53

0.58

3

CORE Well Being Dimension

0.5

0.49

0.03

0.47

0.53

3

EORTC Appetite Loss

0.29

0.3

0.09

0.21

0.37

4

EORTC Cognitive Functioning

0.49

0.49

0.08

0.4

0.59

4

EORTC Constipation

0.39

0.4

0.08

0.3

0.48

4

EORTC Diarrhoea

0.25

0.27

0.07

0.16

0.32

4

EORTC Dyspnoea

0.43

0.44

0.06

0.35

0.49

4

EORTC Emotional Functioning

0.51

0.5

0.06

0.46

0.6

4

EORTC Fatigue

0.56

0.56

0.06

0.49

0.63

4

EORTC Financial Difficulties

0.63

0.62

0.07

0.56

0.74

4

EORTC Insomnia

0.44

0.49

0.12

0.26

0.52

4

EORTC Nausea

0.21

0.18

0.06

0.16

0.3

4

EORTC Pain

0.48

0.48

0.08

0.39

0.58

4

EORTC Physical Functioning

0.59

0.58

0.07

0.52

0.68

4

EORTC QoL

0.55

0.57

0.08

0.44

0.61

4

EORTC Role Functioning

0.54

0.54

0.04

0.5

0.59

4

EORTC Social Functioning

0.51

0.5

0.06

0.43

0.59

4

EPDS

0.49

0.49

0.04

0.47

0.52

2

EQ-5D Utility Score

0.55

0.54

0.13

0.32

0.87

29

EQ-5D VAS

0.41

0.46

0.2

−0.13

0.67

21

GSES

0.52

0.56

0.08

0.44

0.58

3

LEG PAIN

0.16

0.11

0.16

0.04

0.34

3

MFI General Fatigue

0.18

0.18

NA

0.18

0.18

1

MFI Mental Fatigue

0.53

0.53

NA

0.53

0.53

1

MFI Physical Fatigue

0.5

0.5

NA

0.5

0.5

1

MFI Reduced Activity

0.65

0.65

NA

0.65

0.65

1

MFI Reduced Motivation

0.61

0.61

NA

0.61

0.61

1

ODI

0.36

0.36

0.05

0.31

0.41

3

ONS Well-Being

0.62

0.62

NA

0.62

0.62

1

PHQ9

0.66

0.66

0.08

0.53

0.76

6

PISQ-31 Behaviour/Emotion

0.73

0.73

NA

0.73

0.73

1

PISQ-31 Partner Related Factor

0.63

0.63

NA

0.63

0.63

1

PISQ-31 Physical Factor

0.35

0.35

NA

0.35

0.35

1

PISQ-31 Total Score

0.62

0.62

NA

0.62

0.62

1

SF-36 General Health

0.6

0.58

0.08

0.49

0.79

29

SF-36 Mental Component Summary

0.54

0.55

0.12

0.33

0.79

17

SF-36 Mental Health

0.57

0.57

0.11

0.37

0.83

27

SF-36 Pain

0.49

0.51

0.13

0.2

0.71

29

SF-36 Physical Component Summary

0.56

0.6

0.21

0.14

0.84

17

SF-36 Physical Functioning

0.64

0.63

0.17

0.01

0.91

29

SF-36 Role-Emotional

0.42

0.43

0.11

0.12

0.68

31

SF-36 Role-Physical

0.39

0.35

0.12

0.21

0.67

29

SF-36 Social Functioning

0.44

0.45

0.1

0.24

0.63

29

SF-36 Vitality

0.55

0.53

0.1

0.43

0.82

29

SF-36 Health Change

0.32

0.32

0.11

0.24

0.4

2

SF-6D

0.5

0.48

0.09

0.37

0.64

14

Sleep Apnoea QoL

0.56

0.6

0.12

0.35

0.65

5

SPADI

0.47

0.47

0.03

0.44

0.5

3

SPADI Disability

0.49

0.51

0.06

0.43

0.54

3

SPADI Pain

0.36

0.38

0.05

0.31

0.4

3

VAS Pain

0.41

0.41

0.07

0.33

0.48

4

WOMAC Pain

0.26

0.26

NA

0.26

0.26

1

WOMAC Physical Function

0.46

0.46

NA

0.46

0.46

1

WOMAC Stiffness

0.09

0.09

NA

0.09

0.09

1

Back to article page

Trials

ISSN: 1745-6215